Profile of hepatic encephalopathy in children with cirrhosis and response to lactulose
- PMID: 21372353
- PMCID: PMC3099061
- DOI: 10.4103/1319-3767.77246
Profile of hepatic encephalopathy in children with cirrhosis and response to lactulose
Abstract
Background/aim: Hepatic encephalopathy (HE) is associated with a poor prognosis. There is paucity of data on the treatment of HE with lactulose in children with cirrhosis.
Patients and methods: Retrospective analysis of consecutive cirrhotic patients (<18 years) with HE was done. HE was defined according to West-Haven criteria. Response was defined as complete if patients recovered completely from HE, partial response was defined as improvement of encephalopathy by one or more grades from admission but not complete recovery, and defined as non response if patient did not show any improvement or deteriorated further even after 10 days of lactulose therapy.
Results: A total of 300 patients were admitted with cirrhosis and HE (278 adults and 22 children). Of 22 patients, 16 (73%) patients had complete response to lactulose and six (27%) patients did not [three (13.5%) patients worsened (non response) and three (13.5%) did not recover fully even after 10 days of treatment (partial response)]. Comparing baseline characteristics of patients who had complete response (n=16) versus partial (n=3) and non response (n=3), there was significant difference in mean arterial pressure (78.1±10.7 vs 62.6±5.0 mmHg, P=0.003), serum sodium (131.3±3.2 vs 126.5±5.2, P=0.01) and serum creatinine (0.78±0.3 vs 1.1±0.3 mg/dl, P=0.02). We did not find any difference in baseline characteristics of these patients regarding CTP score (9.6±1.2 vs 10.6±1.2), MELD score (17.6±2.9 vs 17.1±3.4), severity of HE (2.5±0.6 vs 2.6±0.5) and etiology of precipitating factors (P=0.78).
Conclusions: Lactulose therapy causes complete recovery from hepatic encephalopathy in 73% of pediatrics patients with cirrhosis.
Conflict of interest statement
Similar articles
-
Predictors of nonresponse to lactulose in patients with cirrhosis and hepatic encephalopathy.Eur J Gastroenterol Hepatol. 2010 May;22(5):526-31. doi: 10.1097/MEG.0b013e3283341b7d. Eur J Gastroenterol Hepatol. 2010. PMID: 20009938 Clinical Trial.
-
Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy.Am J Gastroenterol. 2012 Jul;107(7):1043-50. doi: 10.1038/ajg.2012.113. Epub 2012 Jun 19. Am J Gastroenterol. 2012. PMID: 22710579 Clinical Trial.
-
Lactulose vs polyethylene glycol 3350--electrolyte solution for treatment of overt hepatic encephalopathy: the HELP randomized clinical trial.JAMA Intern Med. 2014 Nov;174(11):1727-33. doi: 10.1001/jamainternmed.2014.4746. JAMA Intern Med. 2014. PMID: 25243839 Free PMC article. Clinical Trial.
-
Update on management of patients with overt hepatic encephalopathy.Hosp Pract (1995). 2013 Aug;41(3):48-59. doi: 10.3810/hp.2013.08.1068. Hosp Pract (1995). 2013. PMID: 23948621 Review.
-
Complications of Cirrhosis in Primary Care: Recognition and Management of Hepatic Encephalopathy.Am J Med Sci. 2018 Sep;356(3):296-303. doi: 10.1016/j.amjms.2018.06.008. Epub 2018 Jun 19. Am J Med Sci. 2018. PMID: 30286824 Review.
Cited by
-
Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis.Cochrane Database Syst Rev. 2016 May 6;2016(5):CD003044. doi: 10.1002/14651858.CD003044.pub4. Cochrane Database Syst Rev. 2016. PMID: 27153247 Free PMC article.
-
Prevalence and Precipitants of Hepatic Encephalopathy in Hospitalized Children With Chronic Liver Disease.J Clin Exp Hepatol. 2024 Nov-Dec;14(6):101452. doi: 10.1016/j.jceh.2024.101452. Epub 2024 May 31. J Clin Exp Hepatol. 2024. PMID: 39005950
-
Management of overt hepatic encephalopathy.J Clin Exp Hepatol. 2015 Mar;5(Suppl 1):S82-7. doi: 10.1016/j.jceh.2014.04.004. Epub 2014 May 10. J Clin Exp Hepatol. 2015. PMID: 26041964 Free PMC article. Review.
-
Disaccharides in the treatment of hepatic encephalopathy.Metab Brain Dis. 2013 Jun;28(2):313-20. doi: 10.1007/s11011-013-9392-4. Epub 2013 Mar 2. Metab Brain Dis. 2013. PMID: 23456517 Review.
-
Cirrhosis in children and adolescents: An overview.World J Hepatol. 2015 Mar 27;7(3):392-405. doi: 10.4254/wjh.v7.i3.392. World J Hepatol. 2015. PMID: 25848466 Free PMC article. Review.
References
-
- Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy--definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology. 2002;35:716–21. - PubMed
-
- Riordan SM, Williams R. Treatment of hepatic encephalopathy. N Engl J Med. 1997;337:473–9. - PubMed
-
- Jalan R, Hayes PC. Hepatic encephalopathy and ascites. Lancet. 1997;350:1309–156. - PubMed
-
- Blei AT, Córdoba J. Practice Parameters Committee of the American College of Gastroenterology. Hepatic encephalopathy. Am J Gastroenterol. 2001;96:1968–76. - PubMed
-
- Uribe M, Berthier JM, Lewis H, Mata JM, Sierra JG, García-Ramos G, et al. Lactose enemas plus placebo tablets versus neomycin tablets plus starch enemas in acute portal systemic encephalopathy.A doubleblind randomized controlled study. Gastroenterology. 1981;81:101–6. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical